🇺🇸 FDA
Patent

US 10512673

Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease

granted A61KA61K38/1709A61K38/1793

Quick answer

US patent 10512673 (Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/1709, A61K38/1793, A61K38/2066, A61K45/06